DUBLIN--(BUSINESS WIRE)--The "Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ResearchAndMarkets.com's offering.
Global Recombinant Plasma Protein Therapeutics Market: Overview
This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Moreover, increase in the number of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid adoption of genetic engineering technologies in healthcare for the development of new therapeutics are also estimated to fuel the market during the forecast period.
The global recombinant plasma protein therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, cell line, indication, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global recombinant plasma protein therapeutics market.
New product launch and FDA approvals are also important factors that are expected to boost the market across the globe. For instance, in April 2018, Shire received FDA approval for VONVENDI recombinant von Willebrand factor indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD)
Key Topics Covered:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016-2026
5. Key Insights
5.1. New Product Launch and Regulatory Approvals
5.2. Key Mergers & Acquisitions
5.3. Regulatory Scenario by Region/Country
6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026
6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class
7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026
7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line
8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026
8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication
9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region
9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region
10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026
10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026
10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026
10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016-2026
10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026
11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026
11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026
11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026
11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026
12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026
12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026
12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026
12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026
13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026
13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026
13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026
13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026
14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026
14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026
14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026
14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
15. Competitive Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2016)
15.3. Company Profiles
15.3.1. CSL Limited
15.3.2. Shire (Takeda Pharmaceutical Company Limited)
15.3.3. Octapharma
15.3.4. Novo Nordisk A/S
15.3.5. Bayer AG
15.3.6. Pfizer Inc.
15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)
15.3.8. Aptevo Therapeutics
15.3.9. Pharming Group NV
For more information about this report visit https://www.researchandmarkets.com/r/4aj3c2
